Skip to content

Evaluation of a palliative day care service for cancer survivors

A randomised controlled trial to evaluate a complex rehabilitative intervention for patients with advanced progressive recurrent cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN22485853
Enrollment
240
Registered
2009-11-09
Start date
2009-10-31
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palliative care for cancer survivors Cancer Malignant neoplasm of other and ill-defined sites

Interventions

Patients who are selected for the intervention group will be offered immediate referral to the day therapy unit and will receive an individual systematic assessment by a senior member of the medical/n

Sponsors

University College London (UCL) (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who are attending Haematology and Breast Outpatient Departments at the Royal Free Hospital, London or University College London Hospitals 2. Patients with active, progressive recurrent malignant disease (first or subsequent remission) 3. Patients aged 18 years and above, either sex 4. Patients who are able to communicate effectively

Exclusion criteria

Exclusion criteria: 1. Patients who are considered to be cured of their malignant disease 2. Patients who have non-malignant disease only 3. Patients under 18 years old 4. Patients who are unable to feedback and communicate effectively

Design outcomes

Primary

MeasureTime frame
The psychological domain on the long form of Supportive Care Needs Survey (SCNS LF59), assessed at baseline and three months follow-up.

Secondary

MeasureTime frame
1. Continuity of care (Continuity of Care measure) 2. Psychological status (KD10) 3. Quality of life (EQ5D) 4. Physical function (measured by the ECOG) 5. Costs associated with the intervention and health service use will also be collected Outcomes will be assessed at baseline and three months follow-up.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026